Should You Buy Biotricity, Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Biotricity, Inc. (BTCY) occupies a solid middle-ground position with a Quality of Company score of 6.0/10. At the current market price of $0.12, the investment case depends heavily on whether our 13 independent valuation models indicate a discount to fair value.
The short answer: 1 of 1 CirclFi valuation models project upside for Biotricity, Inc. (BTCY) at $0.12 — the model consensus leans bullish, with a Quality Score of 6.0/10 and Value-Trap risk of 39/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Biotricity, Inc. (BTCY) in 2026?
What Is the Bull Case vs the Bear Case for Biotricity, Inc. (BTCY)?
| Bull case — $0.49 target (+305.0%) | Bear case |
|---|---|
| According to the CirclFi Deep Alpha Valuation Engine, 1 of 1 models identify upside from $0.12 to a median fair value of $0.49, indicating the market hasn't fully priced in Biotricity, Inc.'s earnings power. | No active model flags significant downside for BTCY. The Value Trap score of 39/100 still argues for some caution. |
| According to the CirclFi Deep Alpha Valuation Engine, the PWERM model targets a fair value of $0.49 (+305.0%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | |
| Industry tailwind: licensing and M&A optionality could provide meaningful support for Biotricity, Inc.'s revenue and margin trajectory in the Medical Devices space. |
How Does BTCY Compare to Its Medical Devices Peers?
Valuation data pages: SSII · LAB · VYCO · XAIR · AIDX · OWLT · RMSL · TCMD · CERS · IRMD · PODD
Which Other Stocks Score Like BTCY on Quality?
Closest companies to BTCY’s Quality of Company score of 6.0/10, across all industries.
- PRM — Perimeter Solutions, Inc. (QOC 6.0) · analysis
- ISCO — International Stem Cell Corporation (QOC 6.0) · analysis
- RANI — Rani Therapeutics Holdings, Inc. (QOC 6.0) · analysis
- SKIN — SkinHealth Systems Inc. (QOC 6.0) · analysis
- NUVB — Nuvation Bio Inc. (QOC 6.0) · analysis
- OSG — Octave Specialty Group, Inc. (QOC 6.0) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Medical Devices Screens Does BTCY Appear In?
So Is Biotricity, Inc. (BTCY) Worth Buying in 2026?
The convergence of 6.0/10 quality, multi-model undervaluation (1/1 bullish, +305.0% median upside), and a median fair value of $0.49 vs. $0.12 current price makes Biotricity, Inc. one of the more compelling opportunities in our coverage. As always, our models provide a quantitative starting point — not a substitute for individual due diligence.
These are quantitative model outputs, not investment recommendations. Biotricity, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About BTCY Stock?
Should I buy BTCY stock right now?
Based on CirclFi's multi-model analysis, 1 of 1 models see upside for BTCY at $0.12. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 6.0/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Biotricity, Inc.?
Key risks include: limited model coverage (1/13 active), reducing analytical confidence; general market and sector-specific risks affecting Medical Devices companies. Always diversify and consult a financial advisor.
How does BTCY compare to its competitors?
Among Medical Devices peers, BTCY holds a Quality Score of 6.0/10. Comparable companies include SSII (QOC 6.0), LAB (QOC 5.9), VYCO (QOC 6.0). The relative ranking helps investors identify whether BTCY offers better fundamental quality than alternatives in the same sector.
Is BTCY a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. BTCY's Quality Score of 6.0/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.
What price should I buy BTCY at?
CirclFi does not provide target buy prices or price alerts. However, our 1 active models produce fair value estimates ranging from $0.49 to $0.49. At $0.12, the stock trades below even the most conservative estimate, which may represent a margin of safety — or reflect risks the models don't capture. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for BTCY.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad